Skip to content

A multicenter randomized controlled trial of transcutaneous acupoint electrical stimulation at Zusanli/Neiguan for the treatment of chronic coronary syndrome

A multicenter randomized controlled trial of transcutaneous acupoint electrical stimulation at Zusanli/Neiguan for the treatment of chronic coronary syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000529
Enrollment
Unknown
Registered
2024-10-12
Start date
2024-09-01
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic coronary syndrome

Interventions

sham- TEAS Neiguan Zusanli group combined with conventional Western medicine treatment group:sham- TEAS Neiguan Zusanli group combined with conventional Western medicine treatment
TEAS Neiguan Zusanli group combined with conventional Western medicine treatment group:TEAS Neiguan Zusanli group combined with conventional Western medicine treatment group

Sponsors

Changchun University of Chinese Medicine Affiliated Third Clinical Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Complies with the 2019 ESC Diagnosis and Guidelines for Chronic Coronary Syndrome; (2) Stable angina pectoris; (3) The grading criteria for angina pectoris refer to the Canadian Cardiovascular Society's severity classification of angina pectoris which is divided into grades I II and III; (4) Age range of 30 to 80 years old male or female not limited; (5) Angina attacks for = 3 months with a weekly frequency of = 2 angina attacks; (6) Sign the informed consent form and voluntarily participate in this study.

Exclusion criteria

Exclusion criteria: (1) Individuals with poor blood pressure and blood sugar control; (2) Patients with severe cardiovascular diseases such as severe cardiopulmonary dysfunction severe arrhythmia severe arterial stenosis dissection etc; (3) Patients with severe cerebrovascular disease liver kidney or hematological disorders or malignant tumors; (4) Individuals with a tendency towards bleeding or allergies; (5) Patients with pacemakers; (6) Pregnant or lactating women or those who have fertility requirements in the past six months; (7) Merge individuals with mental illnesses or unwillingness to cooperate; (8) Individuals who have participated or are currently participating in other clinical trials within the past three months;

Design outcomes

Primary

MeasureTime frame
Frequency of angina attacks;

Secondary

MeasureTime frame
Seattle Angina Scale Score; 6-minute walk test;VAS score for angina pain;dynamic electrocardiogram; Usage of Nitroglycerin or Suxiaojiuxin Pills;serum lipids;electrocardiogram;

Countries

China

Contacts

Public ContactHongfeng Wang

Changchun University of Chinese Medicine

ccwhf123@163.com13234482226

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026